High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
Abstract
Intratumoral injection of cyclic dinucleotide (CDN) agonists of the stimulator of interferon genes (STING) pathway engages innate immune activation and priming of adaptive immune effectors to foster local and distal tumor clearance. Despite proven therapeutic efficacy in preclinical models, a thorough understanding of how CDNs reprogram suppressive myeloid stroma in mouse and man is lacking.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2021
- Source ID
- 10.1136/jitc-2021-003246
Entities
People
- Akash Boda
- Brittany Morrow
- Casey R Ager
- Colm R Duffy
- Cristian Coarfa
- Kimal Rajapakshe
- Maria Emilia Di Francesco
- Meghan A Dean
- Michael A. Curran
- Philip Jones
- Priyamvada Jayaprakash
- Ravaen B Slay
- Rishika Prasad
- Spencer Lea
Organizations
- National Institutes of Health
- Pancreatic Cancer Action Network
- United States Department of Defense